Literature DB >> 19528129

Bayesian clinical trials: no more excuses.

Mithat Gönen.   

Abstract

Mesh：

Year:  2009        PMID： 19528129     DOI： 10.1177/1740774509105374

Source DB:  PubMed          Journal:  Clin Trials        ISSN： 1740-7745            Impact factor:   2.486


× No keyword cloud information.
  13 in total

1.  Biomarker-led adaptive trial blazes a trail in breast cancer.

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2010-05       Impact factor: 54.908

2.  Bayesian adaptive randomized trial design for patients with recurrent glioblastoma.

Authors:  Lorenzo Trippa; Eudocia Q Lee; Patrick Y Wen; Tracy T Batchelor; Timothy Cloughesy; Giovanni Parmigiani; Brian M Alexander
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

3.  Bayesian adaptive randomization designs for targeted agent development.

Authors:  J Jack Lee
Journal:  Clin Trials       Date:  2010-06-22       Impact factor: 2.486

4.  Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update.

Authors:  Rebecca S Slack Tidwell; S Andrew Peng; Minxing Chen; Diane D Liu; Ying Yuan; J Jack Lee
Journal:  Clin Trials       Date:  2019-08-26       Impact factor: 2.486

5.  Dose-finding designs for trials of molecularly targeted agents and immunotherapies.

Authors:  Cody Chiuzan; Jonathan Shtaynberger; Gulam A Manji; Jimmy K Duong; Gary K Schwartz; Anastasia Ivanova; Shing M Lee
Journal:  J Biopharm Stat       Date:  2017-02-06       Impact factor: 1.051

6.  Lessons Learned From Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer.

Authors:  Rebecca S S Tidwell; Peter F Thall; Ying Yuan
Journal:  JCO Precis Oncol       Date:  2021-11-10

Review 7.  Adaptive designs for dual-agent phase I dose-escalation studies.

Authors:  Jennifer A Harrington; Graham M Wheeler; Michael J Sweeting; Adrian P Mander; Duncan I Jodrell
Journal:  Nat Rev Clin Oncol       Date:  2013-03-19       Impact factor: 66.675

8.  AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials.

Authors:  Graham M Wheeler; Michael J Sweeting; Adrian P Mander
Journal:  PLoS One       Date:  2016-07-12       Impact factor: 3.240

9.  Model-Based Assessment of Alternative Study Designs in Pediatric Trials. Part II: Bayesian Approaches.

Authors:  G Smania; P Baiardi; A Ceci; M Cella; P Magni
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-08-17

10.  Changing the Paradigm for the Treatment and Development of New Therapies for FSGS.

Authors:  Cathie Spino; Jordan S Jahnke; David T Selewski; Susan Massengill; Jonathan Troost; Debbie S Gipson
Journal:  Front Pediatr       Date:  2016-03-23       Impact factor: 3.418
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.